

TECHNICAL SHEET

B148	COLUMBIA BLOOD AGAR BASE (W/1% AGAR)	
Formula		
Ingredients :	gms/lit.	
Peptone, special	23.00	
Corn starch	1.00	
Sodium chloride	5.00	
Agar	10.00	
Final pH (at 25°C) : 7.3 ± 0.2		
Directions :		
Suspend 39 grams in 1000 ml distilled water. Heat to boiling to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Cool to 45-50°C before adding heat sensitive compounds.		
For Blood Agar: Add 5% v/v sterile defibrinated sheep blood to sterile cool base.		
For Chocolate Agar: Add 10% v/v sterile defibrinated sheep blood to sterile cool base. Heat to 80°C for 10 minutes with constant agitation. The medium can be made selective by adding different antimicrobials to sterile base.		
For Brucella species: Add rehydrated contents of 1 vial of Brucella Selective Supplement (BF012) to 500 ml sterile molten base.		
For Campylobacter species: Add rehydrated contents of 1 vial of Campylobacter Supplement- I (Blaser-Wang) (BF013) or Campylobacter Supplement- II, (Butzler) (BF014) or Campylobacter Supplement- III (Skirrow) (BF015) or Campylobacter Selective Supplement (BF041) or Campylobacter Supplement- VI (Butzler) (BF042) to 500 ml sterile molten base along with rehydrated contents of 1 vial of Campylobacter Growth Supplement (BF016).		
For Gardnerella species: Add rehydrated contents of 1 vial of G.Vaginalis Selective Supplement (BF040) to 500 ml sterile molten base.		
For Cocci: Add rehydrated contents of 1 vial of Staph-Strepto Supplement (BF148) or Strepto Supplement (BF017) or Streptococcus Selective Supplement (BF043) to 500 ml sterile molten base.		
Principle :		
Columbia Blood Agar Base uses specially selected raw materials to support good growth of fastidious microorganisms. Peptone provides nitrogen, carbon, amino acids and vitamins. Corn starch, increases growth of Neisseria and enhances the hemolytic reactions of some streptococci. Agar is a solidifying agent. Sodium Chloride maintains the osmotic balance of the medium. Blood agar bases are relatively free of reducing sugars, which have been reported to adversely influence the hemolytic reactions of B-hemolytic streptococci. Supplementation with blood (5-10%) provides additional growth factors for fastidious microorganisms and aids in determining hemolytic reactions. Hemolytic patterns may vary with the source of animal blood and the type of basal medium used.		
QC Tests – (I)Dehydrated Medium		
Colour :	Cream to yellow	
Appearance :	Homogeneous Free Flowing powder	
(II)Rehydrated medium		
pH (post autoclaving/heating) :	7.3 ± 0.2	
Colour (post autoclaving/heating) :	A) Basal medium : Light amber B) (After addition of 5% sterile defibrinated blood): Cherry red	
Clarity (post autoclaving/heating) :	A) Clear to slightly opalescent gel. B) Opaque	

Refer disclaimer Overleaf

(III)Q.C. Test Microbiological						
Cultural characteristics observed after 48 hrs. at 35-37°C.						
MICROORGANISM (ATCC)		GROWTH w/5% BLOOD		HAEMOLYSIS		
Neisseria meningitidis (13090)		Luxuriant		None		
Staphylococcus aureus (25923)		Luxuriant		Beta or gamma		
Staphylococcus aureus (6538)		Luxuriant		Beta or gamma		
Staphylococcus epidermidis (12228)		Luxuriant		Gamma		
Streptococcus pneumoniae (6303)		Luxuriant		Alpha		
Streptococcus pyogenes (19615)		Luxuriant		Beta		
Precautions :						
1. For Laboratory Use.						
2. Follow proper, established laboratory procedures in handling and disposing of infectious materials.						
Limitations :						
1. Since the nutritional requirements of organisms vary, some strains may be encountered that fail to grow or grow poorly on this medium.						
Use :						
As a basal medium used for isolation and cultivation of fastidious bacteria.						
Storage :						
Dehydrated medium- below 30°C Prepared medium- Between 2 to 8°C.						
Packing :						
500 gm bottle						
Product profile:		Reconstitution	Quantity on Preparation (500g)	pH (25°C)	Supplement	Sterilization
B148		39g/l	12.82L	7.3 ± 0.2	5% v/v defibrinated blood or as per requirement	sterile sheep per 121°C / 15 minutes

Disclaimer:

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related BIOMARKLABORATORIES publications.

The information contained in this publication is based on our in-house studies and market performance and is to the best of our knowledge true and accurate. BIOMARK LABORATORIES reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.

BIOMARK Laboratories-INDIA

www.biomarklabs.com

TECHNICAL SHEET

Page 02 of 02

Rev: December 2020